A first-of-its-kind cancer vaccine is significantly reducing the chances that melanoma patients’ tumors come back, according to results of a major study released Thursday by drugmakers Moderna and Merck.

Learn how personalized cancer vaccines work and what to watch for at ESMO 2026. A vaccine made from a person’s own tumor has become the first of its kind to succeed in a phase 3 trial. Full results come out Oct.

Moderna and Merck are preparing to seek regulatory approval after their experimental melanoma vaccine delivered promising results in a late-stage clinical trial.

Skepticism about the government’s pandemic response is one thing. Writing off mRNA vaccine technology is another.

For some older adults, the flu vaccine could look a little different this year. In August, the US Food and Drug Administration approved the nation’s first mRNA-based flu vaccine for use in people 50 and older. The vaccine, called mFlusiva, is now ...

A new mRNA flu vaccine made by Moderna was approved by the FDA in August, and is currently available for people aged 50 and over. The promise of an mRNA vaccine for flu is that it can be spun up more quickly than a traditional vaccine, meaning it could ...